Slide 1: H1 FY26 Results Presentation
ATOMO DIAGNOSTICS H1 FY26 RESULTS PRESENTATION 26th February 2026
Slide 2: Who Is Atomo And What Do We Do?
WHO IS ATOMO AND WHAT DO WE DO? Our unique portfolio of patented rapid tests and technologies allows people to test reliability, putting healthcare in the hands of the user WHO IS ATOMO? WHAT BUSINESSES TO WE HAVE? Point of Care Test (POCT) Diagnostic Products: • We develop, manufacture and supply i
Slide 3: H1 FY26 – Activity Summary
H1 FY26 – ACTIVITY SUMMARY • Atomo receives Pascal orders for FebriDx totaling ~A$1.5 million • Pascal performance proven in US clinical studies; delivering greater than 99% usability and supporting submission to US FDA for FebriDx CLIA waiver • Atomo secures two new customers for Pascal • Detection
Slide 4: ASX: AT1 Corporate Snapshot
ASX: AT1 CORPORATE SNAPSHOT Market Cap. Year low – high Shares on issue $30.79M $0.014 - $0.048 810,175,282 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 4
Slide 5: H1 FY26 Financial Performance
H1 FY26 FINANCIAL PERFORMANCE
Slide 6: HY1 - FY26 Profit & Loss
HY1 - FY26 PROFIT & LOSS H1 H1 • Sales increased 6% compared H1 FY25, AUD (%) FY26 ($m) FY25 ($m) 2.18 2.05 6% bringing total revenue to $2.18m for the Revenue (1.33) (1.12) period. Cost of sales Gross Profit 0.85 0.93 (9%) • Gross margin reduced by 6%, primarily driven Gross Margin 39% 45% 37% 37%
Slide 7: HY1 - FY26 Balance Sheet
HY1 - FY26 BALANCE SHEET • Atomo had a cash balance of $3.51m as of 31 H1 FY26 FY25 AUD ($m) ($m) December 2025, and the company remains debt Cash and cash equivalents 3.51 3.22 free Trade and other receivables 1.86 1.69 • Capitalised expenditure relating to R&D and PPE Inventories 1.61 1.65 for the
Slide 8: HY1 - FY26 Cashflow
HY1 - FY26 CASHFLOW • Total Cash Receipts: $4.5 million • ~$2m from product sales Cashflow activities • $875k from R&D tax rebate 9.00 • ~$330k from CRC-P Grant for Active Syphilis 8.00 test development 7.00 • ~$1.3m from capital raised in July 2025 (net 6.00 of transaction costs) 5.00 A$(m) 4.00 •
Slide 9: Fundamentals
FUNDAMENTALS Revenue OpEx Underlying EBITDA Loss* (excl. grants & rebate offsets) H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 2.5 0.0 2 4.0 (0.5) 1.5 3.0 A$(m) A$ (m) (1.0) 1 2.0 A$(m) 0.5 1.0 (1.5) 0 - (2.0) H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 POC Tests POC T
Slide 10: Atomo’s Diagnostic Test Business
ATOMO’S DIAGNOSTIC TEST BUSINESS
Slide 11: Atomo’s HIV Self-Test Business
ATOMO’S HIV SELF-TEST BUSINESS ATOMO IS SEEING TWO KEY DRIVERS OF LONG-TERM GROWTH IN HIV: o Increasing demand in Retail markets post COVID o Emerging Public Health Procurement for Infectious Disease Self-Testing • Continued growth for HIV Self-Test with H1 FY26 revenues of $1.1m and orders received
Slide 12: HIV Self-Test Sales Momentum
HIV SELF-TEST SALES MOMENTUM HIV Rapid Test market estimated at US$1.75 billion, growing at a CARG of 10% * High growth rate in Self-Testing driven by privacy and convenience, and a growing adoption of self-test policy and procurement of self-tests by public health bodies Atomo and NAPWHA collaborat
Slide 13: Unique Active Syphilis Test
UNIQUE ACTIVE SYPHILIS TEST An Increasing Public Health Challenge and Commercial Opportunity: • The global syphilis testing market was valued at $1.1 billion in 2020, and is projected to reach $1.9 billion by 2030 # • Data suggests the UK performed ~1.8 million syphilis tests in 2024, including ~350
Slide 14: Atomo’s Liver Test – Derisked Development Pathway
ATOMO’S LIVER TEST – DERISKED DEVELOPMENT PATHWAY Atomo secures an exclusive worldwide license to commercialise Test Performance: Burnet Institute’s proven ALT / Liver test assay * Test shows good correlation (R2 = 0.9089) between • Atomo will be the listed manufacturer and supplier of the fingerpri
Slide 15: Liver Test – Broad Commercial Utility
LIVER TEST – BROAD COMMERCIAL UTILITY • Monitoring for drug-induced liver injury (DILI) – common drug types where ALT monitoring is recommended; TB Drugs, Methotrexate, Leflunomide & Azathioprine (Immunology and Rheumatology), Valporoate (Neurology), Amiodarone (Cardiovascular) and long-term Diclofe
Slide 16: Atomo’s OEM Cassette Business
ATOMO’S OEM CASSETTE BUSINESS
Slide 17: Pascal OEM Business – H1 FY26 Highlights
PASCAL OEM BUSINESS – H1 FY26 HIGHLIGHTS • Atomo receives H1 FY26 orders for FebriDx totaling ~A$1.5m, representing a ~1600% increase in Pascal FebriDx orders when compared to H1 FY25 • Lumos signs a six-year agreement with PHASE Scientific for supply of FebriDx® in US - Lumos anticipates FebriDx pr
Slide 18: New Pascal OEM Business – Chromacare
NEW PASCAL OEM BUSINESS – CHROMACARE Rapid Test to screen for Iron Deficiency in Point-of-Care Other Tests in active development • Atomo has partnered with Canadian company Chromacare on a rapid test that can measure iron levels (Ferritin), with applications in both professional and at home self tes
Slide 19: New Pascal Business – Pipeline
NEW PASCAL BUSINESS – PIPELINE New UK Customer • Atomo is partnering with a UK company on a novel rapid test that addresses a large unmet clinical need in professional settings • 20,000 Pascal units ordered to support validation and registration requirements. Commercial supply agreement for Pascal a
Slide 20: Operational Expansion
OPERATIONAL EXPANSION Atomo has commenced an Operational expansion to support the growth of the company’s OEM Pascal businesses and Atomo Diagnostic Test products • Increased production capacity and improved margins on supply of Pascal to customers and for use in Atomo finished diagnostic tests • Qu
Slide 21: Investor Highlights
INVESTOR HIGHLIGHTS • Pascal orders for FebriDx growing significantly, with a decision by US FDA on CLIA waiver anticipated. (Lumos has previously disclosed significant contract demand for FebriDx , subject to securing CLIA waiver) • Onboarding new customers on the Pascal platform, with best-in-clas